Canada Markets close in 2 hrs 53 mins

Pfizer Inc. (PFE)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
40.29-0.09 (-0.22%)
As of 01:07PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close40.38
Bid40.35 x 1300
Ask40.36 x 4000
Day's Range40.28 - 40.60
52 Week Range39.23 - 56.32
Avg. Volume23,071,668
Market Cap226.16B
Beta (5Y Monthly)0.58
PE Ratio (TTM)23.60
Earnings DateN/A
Forward Dividend & Yield1.64 (3.76%)
Ex-Dividend DateJan 26, 2023
1y Target EstN/A
  • CNW Group

    CIBC introduces additional Canadian Depositary Receipts ("CDRs")

    CIBC today announced the addition of six new Canadian Depositary Receipts ("CDRs"), now listed on the NEO Exchange.

  • Business Wire

    Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts

    NEW YORK, March 21, 2023--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2023. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2023 Performance Report, to be issued that morning.

  • Business Wire

    FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™

    NEW YORK, March 16, 2023--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted 16 to 1 that available data support the safety and effectiveness of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adult patients who are at high risk for progression to severe illness. The AMDAC's vote, while not binding, will be considered by the FDA when making its dec